Multimeric constructs

Patent metadata

Field	Value
Publication number	US-9815892-B2
Application number	US-201414170257-A
Country	US
Kind code	B2
Filing date	Jan 31, 2014
Priority date	Sep 13, 2004
Publication date	Nov 14, 2017
Grant date	Nov 14, 2017

Abstract

Multimeric fusion proteins of an Ig-like domain of Flt-1 are rendered functional by inclusion of a linker moiety. Vectors encoding the fusion proteins and host cells expressing the fusion proteins can be used therapeutically to block neovascularization in individuals with pathological conditions related to neovascularization. Such conditions include age-related macular degeneration, cancer, psoriasis, proliferative diabetic retinopathy, asthma, uveitis, osteoarthritis, and rheumatoid arthritis. The same means of multimerization used for an Iglike domain of Flt-1, i.e., a linker and a multimerization domain, can be used for other polypeptides, including extracellular receptors, antibody variable regions, cytokines, chemokines, and growth factors.

First claim

The invention claimed is:

1. A method of inhibiting VEGF-dependent neovascularization in an eye comprising delivering to a cell in the eye via intraocular delivery, a nucleic acid molecule that encodes a fusion protein of the formula X—Y—Z, wherein
X comprises the Ig-like domain 2 of VEGF-R1 but lacks the Ig-like domains 1 and 3 of a VEGF receptor, with said Ig-like domain 2 of VEGF-R1 being covalently linked to moiety Z via moiety Y;
Y is selected from the group consisting of gly 9 (SEQ ID NO: 27), glu 9 (SEQ ID NO: 28), ser 9 (SEQ ID NO: 29), gly 5 -cys-pro 2 -cys (SEQ ID NO: 30), (gly 4 ser) 3 (SEQ ID NO: 31), Ser-Cys-Val-Pro-Leu-Met-Arg-Cys-Gly-Gly-Cys-Cys-Asn (SEQ ID NO: 32), Pro-Ser-Cys-Val-Pro-Leu-Met-Arg-Cys-Gly-Gly-Cys-Cys-Asn (SEQ ID NO: 13), Gly-Asp-Leu-Ile-Tyr-Arg-Asn-Gln-Lys (SEQ ID NO: 26), and Gly 9 -Pro-Ser-Cys-Val-Pro-Leu-Met-Arg-Cys-Gly-Gly-Cys-Cys-Asn (SEQ ID NO: 34), and
Z is a CH3 region of an IgG heavy chain molecule or an Fc portion of an antibody molecule,
whereby an effective amount of said fusion protein is expressed in the cell and secreted, thereby inhibiting VEGF-dependent neovascularization in the eye.

2. The method of claim 1 , wherein the fusion protein comprises a sequence selected from the group consisting of SEQ ID NO: 2, 8, 21, 23, and 25.

3. The method of claim 1 , wherein the nucleic acid is delivered in vivo.

4. The method of claim 1 , wherein Z is an Fc portion of an antibody molecule.

5. The method of claim 1 , wherein X consists of the Ig-like domain 2 of VEGF-R1 (Flt-1).

Assignees

• Genzyme Corp

Inventors

• Scaria Abraham
• Pechan Peter
• Wadsworth Samuel

Classifications

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title

• A61P27/02

  Ophthalmic agents · CPC title